Castle Biosciences, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Derek J. Maetzold
- Full Time Employees
- 784
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 505 South Friendswood Drive Friendswood TX United States of America 77546
- IPO Date
- Jul 25, 2019
- CIK
- 0001447362
- Website
- castlebiosciences.com
- Similar Companies
- Business
- Castle Biosciences, Inc. (Nasdaq: CSTL) develops and commercializes molecular diagnostic tests that guide patient care for dermatologic cancers, Barrett's esophagus, uveal melanoma, and related conditions; its core portfolio includes DecisionDx-Melanoma, a 31-gene expression profile (GEP) test predicting metastasis risk, sentinel lymph node positivity, and recurrence in invasive cutaneous melanoma; TissueCypher, a spatial-omics risk stratification test predicting progression to high-grade dysplasia or esophageal cancer in Barrett's esophagus patients with non-dysplastic, indefinite, or low-grade dysplasia; DecisionDx-SCC, a 40-GEP test assessing metastasis risk, adjuvant radiation therapy benefit, and local recurrence in high-risk cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test aiding differentiation of melanocytic lesions; DecisionDx-UM, a GEP test with PRAME refinement predicting metastasis in uveal melanoma; and AdvanceAD-Tx, a 487-GEP test guiding systemic treatment selection for moderate-to-severe atopic dermatitis patients aged 12 and older. The company, founded in 2008 and headquartered in Friendswood, Texas, operates laboratories in Phoenix, Arizona, and Pittsburgh, Pennsylvania, serving clinicians in dermatology, gastroenterology, and oncology primarily in the United States. Recent developments include the May 2025 acquisition of Capsulomics, Inc. (d/b/a Previse), adding methylation-based technology to enhance gastrointestinal offerings and enable multiomics approaches for Barrett's esophagus and non-endoscopic sampling; a June 2025 collaboration and license agreement with SciBase Holding AB leveraging electrical impedance spectroscopy for an atopic dermatitis flare prediction test; discontinuation of the IDgenetix pharmacogenomic test for mental health conditions in May 2025; FDA Breakthrough Device designation for DecisionDx-Melanoma in July 2025; and the launch of AdvanceAD-Tx to address biologic treatment decisions in atopic dermatitis.
First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
Castle Biosciences Reports First Quarter 2026 Results
Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas